Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torasemide bioequivalence study in healthy volunteers
NCT07201584Phase 1Recruiting
- Sponsor
- Menarini Group
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of torasemide (2 arms), sponsored by Menarini Group. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration at 24 hours. Started Sep 2025; status: recruiting.
02
Drugs
torasemide
Beyond the preview
Go deeper on NCT07201584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201584.